FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Categories Cancer Risk
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Human Research
Study : Does prior antidepressant use affect the treatment breast cancer patients receive?
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Human Research
Most relevant for: Women diagnosed with breast cancer who have received antidepressants
Previous research found an association between depression and survival in breast cancer patients, but the reasons for this association are unclear. Researchers in this study found that women who had been previously prescribed antidepressants were less likely to receive breast cancer treatment that followed national guidelines than those who had not. Although the difference was small, it underscores the need for patients to discuss any history of depression with their health care providers. (1/24/17)
Read More
Relevance: Medium-High
Strength of Science: Medium
Study : Women with breast cancer symptoms but no lump may wait longer to seek medical care
Relevance: Medium-High
Strength of Science: Medium
Most relevant for: People with breast cancer symptoms
Some patients take longer than others before getting a potential breast cancer checked by their health care provider. Believing that women who have breast cancer symptoms but have no lump may wait longer, researchers in this study used data from women who were diagnosed with breast cancer in 2009 and 2010 to identify possible explanations. (1/18/17)
Read More
Relevance: Medium-High
Quality of Writing: Medium
Personal Story : Men get breast cancer too
Relevance: Medium-High
Quality of Writing: Medium
Most relevant for: Men diagnosed with breast cancer
Cathy Free's piece for People, “Men Have Breasts Too: New York Man Who Survived Stage 2 Breast Cancer Spreads Message,” tells the stories of two men whose experiences with breast cancer inspired them to speak openly about breast cancer awareness for men. (11/29/16)
Read More
Personal Story : Why one woman passed on genetic testing
Most relevant for: People considering genetic testing and people who are Ashkenazi Jewish
What are reasons to get or not get genetic testing? Cynthia Graber gives her thoughts on the matter in her Wired opinion piece, "Why I Won't Get the Genetic Test for Breast Cancer." (11/15/16)
Read More
Study : Removing ovaries before age 50 may increase the risk of chronic conditions for some women
Most relevant for: Women under 50 years of age who have had or are considering removing their ovaries
Removal of ovaries and fallopian tubes prevents ovarian cancer, but it may come with other health risks. Experts recommend removal of ovaries and fallopian tubes in women at high risk for ovarian cancer due to inherited mutations in BRCA or other genes linked to ovarian cancer risk. For these high-risk women the benefit of ovarian cancer prevention outweighs the risk of long-term complications. Based on a recent study, some researchers feel that for women who are not at increased risk for cancer, the risk for some chronic conditions is too high to consider removal of both ovaries. (11/1/16)
Read More
Study : Breast cancer mortality among Hispanic women in the United States varies by country of origin
Most relevant for:
"Hispanic" is a broad ethnic category that includes people from numerous countries. When discussing breast cancer statistics, Mexicans, Cubans, Puerto Ricans and people whose families originated in Central and South America are typically grouped into one Hispanic category. A new study looked at whether the country of origin affected breast cancer prevalence and mortality rates in Hispanic women in the U.S. (10/25/16) Este artículo está disponible en español.
Read More
Study : Breast cancer screening should be tailored to a woman’s risk factors and breast density
Most relevant for: Women who are at high risk for breast cancer due to family history, dense breasts, LCIS, or multiple biopsies
The United States Preventative Services Task Force (USPSTF) recommends a screening mammogram every other year for women ages 50-74 who are at average risk for breast cancer. But do all patients in this category benefit from this screening regimen? 10/18/16
Read More
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Study : Rare mutations in PALB2, CHEK2, and ATM: how much do they increase cancer risk?
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Most relevant for: People who tested positive for one of the rare variants in CHEK2, ATM or PALB2 that are covered in this study
As multi-gene panel tests become more common, people are discovering they have mutations in genes that are not understood as well as BRCA. This can make it difficult to give patients accurate assessments of their cancer risk. For example, mutations in PALB2, CHEK2, and ATM are rare, but some specific changes in these genes are even less common. The goal of this international collaboration was to better understand the cancer risks of some very rare PALB2, CHEK2, and ATM mutations. The findings are relevant only to the specific mutations covered in this paper and do not apply to all people with mutations in PALB2, CHEK2, or ATM. (9/27/16)
Read More
Study : Does IVF increase a woman’s risk for breast cancer?
Most relevant for: Woman at average risk for breast cancer who have or are considering undergoing In Vitro Fertilization
In vitro fertilization (IVF) wasn't commonly used until the 1980s, so its long-term effects are mostly unknown. A new study suggests that the treatment does not increase a woman's risk for developing breast cancer. (8/23/16)
Read More
Relevance: Medium
Strength of Science: Medium
Research Timeline: Human Research
Study : Early research on a drug to prevent breast cancer
Relevance: Medium
Strength of Science: Medium
Research Timeline: Human Research
Most relevant for: Women with a BRCA1 mutation
Many researchers are interested in non-surgical options to reduce the higher-than-average risk of developing breast cancer in BRCA mutation carriers. This research study identified a type of drug, called a “RANK ligand inhibitor,” that may prevent breast cancer. Among mice that were genetically engineered to have no BRCA1 genes, those that were given the drug developed tumors less frequently than those that did not. While this is an exciting early study for BRCA mutation carriers, more work and human clinical trials need to be done before this can be used as a prevention therapy in humans. (7/12/16)
Update added 11/24/19: The RANK ligand inhibitor, denosumab is currently being studied as a possible breast and ovarian cancer preventive agent in human clinical trials.
Read More